Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.

Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV.

Lancet Oncol. 2019 Sep 30. pii: S1470-2045(19)30503-0. doi: 10.1016/S1470-2045(19)30503-0. [Epub ahead of print]

PMID:
31582354
2.

Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia.

Giacopelli B, Zhao Q, Ruppert AS, Agyeman A, Weigel C, Wu YZ, Gerber MM, Rabe KG, Larson MC, Lu J, Blachly JS, Rogers KA, Wierda WG, Brown JR, Rai KR, Keating M, Rassenti LZ, Kipps TJ, Zenz T, Shanafelt TD, Kay NE, Abruzzo LV, Coombes KR, Woyach JA, Byrd JC, Oakes CC.

Blood. 2019 Aug 22;134(8):688-698. doi: 10.1182/blood.2019000490. Epub 2019 Jul 10.

3.

CytoGPS: A Web-Enabled Karyotype Analysis Tool for Cytogenetics.

Abrams ZB, Zhang L, Abruzzo LV, Heerema NA, Li S, Dillon T, Rodriguez R, Coombes KR, Payne PRO.

Bioinformatics. 2019 Jul 2. pii: btz520. doi: 10.1093/bioinformatics/btz520. [Epub ahead of print]

PMID:
31263896
4.

Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing.

Zucker MR, Abruzzo LV, Herling CD, Barron LL, Keating MJ, Abrams ZB, Heerema N, Coombes KR.

Bioinformatics. 2019 Sep 1;35(17):3216. doi: 10.1093/bioinformatics/btz243. No abstract available.

5.

Intricacies of CLL cytogenetic complexity.

Abruzzo LV.

Blood. 2019 Mar 14;133(11):1168-1170. doi: 10.1182/blood-2019-01-896068. No abstract available.

PMID:
30872270
6.

Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing.

Zucker MR, Abruzzo LV, Herling CD, Barron LL, Keating MJ, Abrams ZB, Heerema N, Coombes KR.

Bioinformatics. 2019 Sep 1;35(17):2924-2931. doi: 10.1093/bioinformatics/btz057. Erratum in: Bioinformatics. 2019 Sep 1;35(17):3216.

PMID:
30689715
7.

Correction: Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6.

Li J, Xu J, Abruzzo LV, Tang G, Li S, You MJ, Lu G, Jabbour EJ, Deng Q, Bueso-Ramos CE, Medeiros LJ, Yin CC.

Oncotarget. 2018 Sep 28;9(76):34449. doi: 10.18632/oncotarget.26205. eCollection 2018 Sep 28.

8.

Thirty biologically interpretable clusters of transcription factors distinguish cancer type.

Abrams ZB, Zucker M, Wang M, Asiaee Taheri A, Abruzzo LV, Coombes KR.

BMC Genomics. 2018 Oct 11;19(1):738. doi: 10.1186/s12864-018-5093-z.

9.

Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways.

Abruzzo LV, Herling CD, Calin GA, Oakes C, Barron LL, Banks HE, Katju V, Keating MJ, Coombes KR.

Haematologica. 2018 Dec;103(12):2069-2078. doi: 10.3324/haematol.2018.190132. Epub 2018 Jul 5.

10.

MYC protein expression is an important prognostic factor in acute myeloid leukemia.

Ohanian M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, Loghavi S, Kadia T, Futreal A, Bhalla K, Zuo Z, Huh YO, Post SM, Ruvolo P, Garcia-Manero G, Andreeff M, Kornblau S, Borthakur G, Hu P, Medeiros LJ, Takahashi K, Hornbaker MJ, Zhang J, Nogueras-González GM, Huang X, Verstovsek S, Estrov Z, Pierce S, Ravandi F, Kantarjian HM, Bueso-Ramos CE, Cortes JE.

Leuk Lymphoma. 2019 Jan;60(1):37-48. doi: 10.1080/10428194.2018.1464158. Epub 2018 May 9.

PMID:
29741984
11.

Acute myeloid leukemia with t(4;12)(q12;p13): an aggressive disease with frequent involvement of PDGFRA and ETV6.

Li J, Xu J, Abruzzo LV, Tang G, Li S, You MJ, Lu G, Jabbour EJ, Deng Q, Bueso-Ramos CE, Medeiros LJ, Yin CC.

Oncotarget. 2017 Dec 15;9(13):10987-10994. doi: 10.18632/oncotarget.23743. eCollection 2018 Feb 16. Erratum in: Oncotarget. 2018 Sep 28;9(76):34449.

12.

Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib.

Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, Lozanski G, Zhao W, Gordon AL, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Blum KA, T Awan F, Rogers KA, Grever MR, Johnson AJ, Abruzzo LV, Hertlein EK, Blachly JS, Woyach JA, Byrd JC.

Blood Adv. 2017 Aug 21;1(19):1584-1588. doi: 10.1182/bloodadvances.2017007302. eCollection 2017 Aug 22.

13.

Ocular extramedullary myeloid leukaemia.

Ohanian M, Pemmaraju N, Rozovski U, Alattar ML, Estrov Z, Kundra V, Tung C, Ravandi F, Manning J, Abruzzo LV.

Br J Haematol. 2018 Mar;180(5):738-740. doi: 10.1111/bjh.14430. Epub 2016 Nov 23. No abstract available.

PMID:
27879987
14.

Synergy: karyotypes and mutations in CLL.

Abruzzo LV.

Blood. 2016 Jul 21;128(3):319-20. doi: 10.1182/blood-2016-06-719898. No abstract available.

15.

Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype.

Huh YO, Tang G, Talwalkar SS, Khoury JD, Ohanian M, Bueso-Ramos CE, Abruzzo LV.

Cancer Genet. 2016 Jul-Aug;209(7-8):313-20. doi: 10.1016/j.cancergen.2016.05.072. Epub 2016 May 27.

PMID:
27318442
16.

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.

Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ.

Nat Commun. 2016 May 20;7:11589. doi: 10.1038/ncomms11589.

17.

Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.

Ohanian M, Bueso-Ramos C, Ok CY, Lin P, Patel K, Alattar ML, Khoury JD, Rozovski U, Estrov Z, Huh YO, Cortes J, Abruzzo LV.

Cancer Genet. 2015 Nov;208(11):571-4. doi: 10.1016/j.cancergen.2015.06.004. Epub 2015 Jun 25.

18.

Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.

Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC.

Am J Hematol. 2015 Nov;90(11):967-9. doi: 10.1002/ajh.24125. Epub 2015 Oct 12.

19.

B-Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia: A Report of Four Cases.

Chakhachiro Z, Yin CC, Abruzzo LV, Aladily TN, Barron LL, Banks HE, Thomas DA, Keating M, Medeiros LJ, Huh YO.

Am J Clin Pathol. 2015 Aug;144(2):333-40. doi: 10.1309/AJCPXE5VMONMVLZ0.

PMID:
26185320
20.

Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells.

Yin CC, Tang G, Lu G, Feng X, Keating MJ, Medeiros LJ, Abruzzo LV.

Mod Pathol. 2015 Aug;28(8):1130-7. doi: 10.1038/modpathol.2015.58. Epub 2015 May 8.

21.

Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia.

Strati P, Abruzzo LV, Wierda WG, O'Brien S, Ferrajoli A, Keating MJ.

Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):420-7. doi: 10.1016/j.clml.2015.02.001. Epub 2015 Feb 11.

22.

Isolated mesenteric CD20-positive myeloid sarcoma.

Ohanian M, Huang RS, Yakoushina TV, Estrov Z, Juneja H, Chen L, Idowu M, Abruzzo LV.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):e217-20. doi: 10.1016/j.clml.2014.06.027. Epub 2014 Jun 26. No abstract available.

23.

Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis.

Poon ML, Fox PS, Samuels BI, O'Brien S, Jabbour E, Hsu Y, Gulbis A, Korbling M, Champlin R, Abruzzo LV, Bassett RL, Khouri IF.

Leuk Lymphoma. 2015 Mar;56(3):711-5. doi: 10.3109/10428194.2014.930848. Epub 2014 Aug 4.

24.

B acute lymphoblastic leukemia with t(14;19)(q32;p13.1) involving IGH/EPOR: a clinically aggressive subset of disease.

Jaso JM, Yin CC, Lu VW, Zhao M, Abruzzo LV, You MJ, Yang Y, Luthra R, Medeiros LJ, Lu G.

Mod Pathol. 2014 Mar;27(3):382-9. doi: 10.1038/modpathol.2013.149. Epub 2013 Sep 13.

25.

DEAR1 is a chromosome 1p35 tumor suppressor and master regulator of TGF-β-driven epithelial-mesenchymal transition.

Chen N, Balasenthil S, Reuther J, Frayna A, Wang Y, Chandler DS, Abruzzo LV, Rashid A, Rodriguez J, Lozano G, Cao Y, Lokken E, Chen J, Frazier ML, Sahin AA, Wistuba II, Sen S, Lott ST, Killary AM.

Cancer Discov. 2013 Oct;3(10):1172-89. doi: 10.1158/2159-8290.CD-12-0499. Epub 2013 Jul 9.

26.

Plasma cell enrichment enhances detection of high-risk cytogenomic abnormalities by fluorescence in situ hybridization and improves risk stratification of patients with plasma cell neoplasms.

Lu G, Muddasani R, Orlowski RZ, Abruzzo LV, Qazilbash MH, You MJ, Wang Y, Zhao M, Chen S, Glitza IC, Medeiros LJ.

Arch Pathol Lab Med. 2013 May;137(5):625-31. doi: 10.5858/arpa.2012-0209-OA.

27.

Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes.

Schweighofer CD, Coombes KR, Majewski T, Barron LL, Lerner S, Sargent RL, O'Brien S, Ferrajoli A, Wierda WG, Czerniak BA, Medeiros LJ, Keating MJ, Abruzzo LV.

J Mol Diagn. 2013 Mar;15(2):196-209. doi: 10.1016/j.jmoldx.2012.09.006. Epub 2012 Dec 27.

28.

Chronic lymphocytic leukemia with t(14;18)(q32;q21).

Tang G, Banks HE, Sargent RL, Medeiros LJ, Abruzzo LV.

Hum Pathol. 2013 Apr;44(4):598-605. doi: 10.1016/j.humpath.2012.07.005. Epub 2012 Oct 16.

PMID:
23084581
29.

Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.

Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, Montes-Moreno S, Dybkaer K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Zhao XF, Choi WW, Zhao X, van Krieken JH, Huang Q, Huh J, Ai W, Ponzoni M, Ferreri AJ, Zhou F, Kahl BS, Winter JN, Xu W, Li J, Go RS, Li Y, Piris MA, Møller MB, Miranda RN, Abruzzo LV, Medeiros LJ, Young KH.

Blood. 2012 Nov 8;120(19):3986-96. doi: 10.1182/blood-2012-05-433334. Epub 2012 Sep 5.

30.

Relax with CouchDB--into the non-relational DBMS era of bioinformatics.

Manyam G, Payton MA, Roth JA, Abruzzo LV, Coombes KR.

Genomics. 2012 Jul;100(1):1-7. doi: 10.1016/j.ygeno.2012.05.006. Epub 2012 May 17.

31.

A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia.

Schweighofer CD, Coombes KR, Barron LL, Diao L, Newman RJ, Ferrajoli A, O'Brien S, Wierda WG, Luthra R, Medeiros LJ, Keating MJ, Abruzzo LV.

PLoS One. 2011;6(12):e28277. doi: 10.1371/journal.pone.0028277. Epub 2011 Dec 14.

32.

Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia.

Ma D, Chen Z, Patel KP, Mishra BM, Yao H, Abruzzo LV, Medeiros LJ, Wierda W, Keating M, Sargent R, Luthra R.

Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S17-24. doi: 10.1016/j.clml.2011.03.031. Epub 2011 May 5.

33.

Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance.

Jain P, Javdan M, Feger FK, Chiu PY, Sison C, Damle RN, Bhuiya TA, Sen F, Abruzzo LV, Burger JA, Rosenwald A, Allen SL, Kolitz JE, Rai KR, Chiorazzi N, Sherry B.

Haematologica. 2012 Apr;97(4):599-607. doi: 10.3324/haematol.2011.047316. Epub 2011 Nov 4.

34.

Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib.

Quintás-Cardama A, Kantarjian H, Shan J, Jabbour E, Abruzzo LV, Verstovsek S, Garcia-Manero G, O'Brien S, Cortes J.

Cancer. 2011 Nov 15;117(22):5085-93. doi: 10.1002/cncr.26147. Epub 2011 Apr 26.

35.

Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features.

Huh YO, Schweighofer CD, Ketterling RP, Knudson RA, Vega F, Kim JE, Luthra R, Keating MJ, Medeiros LJ, Abruzzo LV.

Am J Clin Pathol. 2011 May;135(5):686-96. doi: 10.1309/AJCPOEFP3SLX6HXJ.

PMID:
21502423
36.

LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients.

Duzkale H, Schweighofer CD, Coombes KR, Barron LL, Ferrajoli A, O'Brien S, Wierda WG, Pfeifer J, Majewski T, Czerniak BA, Jorgensen JL, Medeiros LJ, Freireich EJ, Keating MJ, Abruzzo LV.

Blood. 2011 Apr 14;117(15):4076-84. doi: 10.1182/blood-2010-09-304881. Epub 2011 Feb 10.

37.

A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Zuo Z, Jones D, Yao H, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Abruzzo LV, Medeiros LJ, Chen SS, Luthra R.

Mod Pathol. 2010 Nov;23(11):1524-34. doi: 10.1038/modpathol.2010.137. Epub 2010 Aug 20.

38.

The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy.

Schweighofer CD, Huh YO, Luthra R, Sargent RL, Ketterling RP, Knudson RA, Barron LL, Medeiros LJ, Keating MJ, Abruzzo LV.

Int J Cancer. 2011 Jun 1;128(11):2759-64. doi: 10.1002/ijc.25605. Epub 2010 Oct 26.

39.

Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features.

Wang SA, Abruzzo LV, Hasserjian RP, Zhang L, Hu Y, Zhang Y, Zhao M, Galili N, Raza A, Medeiros LJ, Garcia-Manero G, Miranda RN.

Leuk Res. 2011 Mar;35(3):351-7. doi: 10.1016/j.leukres.2010.07.018. Epub 2010 Aug 5.

PMID:
20691474
40.

Differential expression of CKS-1B in typical and blastoid variants of mantle cell lymphoma.

Akyurek N, Drakos E, Giaslakiotis K, Knoblock RJ, Abruzzo LV, Ning Y, Rassidakis GZ, Medeiros LJ.

Hum Pathol. 2010 Oct;41(10):1448-55. doi: 10.1016/j.humpath.2010.04.001. Epub 2010 Aug 4.

PMID:
20688354
41.

Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.

Admirand JH, Knoblock RJ, Coombes KR, Tam C, Schlette EJ, Wierda WG, Ferrajoli A, O'Brien S, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV.

Mod Pathol. 2010 Nov;23(11):1518-23. doi: 10.1038/modpathol.2010.131. Epub 2010 Jul 23.

42.

Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome.

Talwalkar SS, Yin CC, Naeem RC, Hicks MJ, Strong LC, Abruzzo LV.

Arch Pathol Lab Med. 2010 Jul;134(7):1010-5. doi: 10.1043/2009-0015-OA.1.

PMID:
20586629
43.

microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival.

Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA.

Blood. 2010 Aug 12;116(6):945-52. doi: 10.1182/blood-2010-01-263889. Epub 2010 Apr 14.

44.

Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification.

Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, Abruzzo LV, Kantarjian HM, Medeiros LJ, Wang SA.

Blood. 2010 Mar 11;115(10):1985-92. doi: 10.1182/blood-2009-09-243964. Epub 2009 Dec 29.

45.

Chronic myeloid leukemia in blast phase associated with t(3;8)(q26;q24).

Lin P, Lennon PA, Yin CC, Abruzzo LV.

Cancer Genet Cytogenet. 2009 Sep;193(2):119-22. doi: 10.1016/j.cancergencyto.2009.04.025.

PMID:
19665075
46.

del(15q) is a recurrent minor-route cytogenetic abnormality in the clonal evolution of chronic myelogenous leukemia.

Yin CC, Abruzzo LV, Qiu X, Apostolidou E, Cortes JE, Medeiros LJ, Lu G.

Cancer Genet Cytogenet. 2009 Jul;192(1):18-23. doi: 10.1016/j.cancergencyto.2009.02.017.

47.

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience.

Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O'Brien S, Ferrajoli A, Lerner SA, Lynn A, Kay NE, Keating MJ.

Blood. 2009 Jul 30;114(5):957-64. doi: 10.1182/blood-2009-03-210591. Epub 2009 May 4.

48.

Chronic lymphocytic leukemia With t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes.

Yin CC, Lin KI, Ketterling RP, Knudson RA, Medeiros LJ, Barron LL, Huh YO, Luthra R, Keating MJ, Abruzzo LV.

Am J Clin Pathol. 2009 May;131(5):663-70. doi: 10.1309/AJCPXLY46UPFLISC.

PMID:
19369625
49.

Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome.

Gustafson SA, Lin P, Chen SS, Chen L, Abruzzo LV, Luthra R, Medeiros LJ, Wang SA.

Am J Clin Pathol. 2009 May;131(5):647-55. doi: 10.1309/AJCP5ETHDXO6NCGZ.

PMID:
19369623
50.

Atypical 11q deletions identified by array CGH may be missed by FISH panels for prognostic markers in chronic lymphocytic leukemia.

Gunn SR, Hibbard MK, Ismail SH, Lowery-Nordberg M, Mellink CH, Bahler DW, Abruzzo LV, Enriquez EL, Gorre ME, Mohammed MS, Robetorye RS.

Leukemia. 2009 May;23(5):1011-7. doi: 10.1038/leu.2008.393. Epub 2009 Jan 22. No abstract available.

PMID:
19158838

Supplemental Content

Loading ...
Support Center